Skip to Content

Menu Icon
Menu

Published on January 01, 2017

NKCH Exceeds its First Year TAVR Goal

North Kansas City Hospital recently celebrated the one-year mark of its transcatheter aortic valve replacement (TAVR) program. TAVR is an innovative approach to treating people with severe symptomatic aortic stenosis. The first two TAVR patients – ages 93 and 96 years old – completed their 12-month testing in July 2016.

“We are pleased with the clinical outcomes of the 39 patients who underwent the TAVR procedure in the first year of our program,” said Zafir A. Hawa, MD, FACC, FSCAI, an interventional cardiologist with Meritas Health Cardiology. “TAVR improved their quality of life.”

Surpassing Expectations

The TAVR team exceeded its goal by nearly 50%, performing 39 successful TAVR procedures, 19 more than the 20 procedures required to keep the program operational. First-year outcomes indicate the program is on par with outcomes from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, which includes approximately 430 TAVR facilities nationwide.

Evolving Care

Previously approved only for high risk patients with comorbidities that make them poor candidates for open heart surgery, the indication was recently expanded to include intermediate risk patients.

“Expanding the indication for TAVR to intermediate risk patients is an important step because if gives a new group of people access to this lifesaving procedure,” said James H. Mitchell, MD, FACC.

NKCH TAVR Team

The specialized TAVR physician team includes two interventional cardiologists, two cardiac surgeons, an anesthesiologist and supporting clinical staff.

Zafir A. Hawa, MD, FACC, FSCAI

Zafir A. Hawa, MD, FACC, FSCAI

Meritas Health Cardiology

James H. Mitchell, MD, FACC

James H. Mitchell, MD, FACC

Meritas Health Cardiology

Keith B. Allen, MD

Keith B. Allen, MD

Mid America Heart and Lung Surgeons

Alexander F. Pak, MD

Alexander F. Pak, MD

Mid America Heart and Lung Surgeons